Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default
With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on its loan from Oxford Finance LLC.
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default Read More »
